Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ruxolitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 known ✓ | O60674 | 14/20 | 0.90 |
| ▸ | JAK1 known ✓ | P23458 | 13/20 | 0.90 |
| ▸ | JAK3 | P52333 | 5/20 | 0.90 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.90 |
| ▸ | PAK4 | O96013 | 2/20 | 0.90 |
| ▸ | ABL1 | P00519 | 2/20 | 0.90 |
| ▸ | RET | P07949 | 2/20 | 0.90 |
| ▸ | LTK | P29376 | 2/20 | 0.90 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.90 |
| ▸ | CLK2 | P49760 | 2/20 | 0.90 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.90 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.90 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.90 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.90 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.90 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.90 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.90 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.90 |
| ▸ | CAMK1D | Q8IU85 | 2/20 | 0.90 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ruxolitinib SCHEMBL29661013 | 1.00 | JAK2 (0.90) | JAK2JAK1JAK3DAPK3PAK4 | |
| Ruxolitinib SCHEMBL22127335 | 1.00 | JAK2 (0.90) | JAK2JAK1JAK3DAPK3PAK4 | |
| Ruxolitinib SCHEMBL29677353 | 0.95 | JAK2 (1.00) | JAK2JAK1JAK3DAPK3PAK4 | |
| Ruxolitinib SCHEMBL31247553 | 0.95 | JAK2 (1.00) | JAK2JAK1JAK3DAPK3PAK4 | |
| Ruxolitinib SCHEMBL99225 | 0.95 | JAK2 (1.00) | JAK2JAK1JAK3DAPK3PAK4 | |
| Ruxolitinib SCHEMBL29349794 | 0.95 | JAK2 (1.00) | JAK2JAK1JAK3DAPK3PAK4 | |
| Ruxolitinib SCHEMBL29808249 | 0.95 | JAK2 (1.00) | JAK2JAK1JAK3DAPK3PAK4 | |
| Ruxolitinib SCHEMBL101279 | 0.95 | JAK2 (1.00) | JAK2JAK1JAK3DAPK3PAK4 | |
| Ruxolitinib SCHEMBL171319 | 0.95 | JAK2 (1.00) | JAK2JAK1JAK3DAPK3PAK4 | |
| Ruxolitinib SCHEMBL26927161 | 0.95 | JAK2 (1.00) | JAK2JAK1JAK3DAPK3PAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727526-A1 | TOPICAL SKIN FORMULATIONS OF A PHARMACEUTICALLY ACCEPTABLE SALT OF RUXOLITINIB | Incyte Corporation (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4629993-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | Kartos Therapeutics (US) | 2025-10-15 | — | — | EP | claimed |
| WO-2024124240-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | KARTOS THERAPEUTICS (US) | 2024-06-13 | — | — | WO | claimed |
| US-20220288078-A1 | Salts of the Janus Kinase Inhibitor (R)-3-(4-(7h-Pyrrolo[2,3-D]Pyrimidin-4-YL)-1h-Pyrazol-1-Yl)-3- Cyclopentylpropanenitrile | INCYTE CORPORATION | 2022-09-15 | — | — | US | claimed |
| EP-2173752-B2 | SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO(2,3-D)PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE | INCYTE HOLDINGS CORP (US) | 2022-07-13 | — | — | EP | claimed |
| EP-3495369-B1 | USE OF SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H- PYRAZOL-1-YL)-3- CYCLOPENTYLPROPANENITRILE | INCYTE HOLDINGS CORP (US) | 2021-10-27 | — | — | EP | claimed |
| EP-3495369-A1 | USE OF SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H- PYRAZOL-1-YL)-3- CYCLOPENTYLPROPANENITRILE | Incyte Holdings Corporation (US) | 2019-06-12 | — | — | EP | claimed |
| EP-3070090-B1 | USE OF SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H- PYRAZOL-1-YL)-3- CYCLOPENTYLPROPANENITRILE | INCYTE HOLDINGS CORP (US) | 2018-12-12 | — | — | EP | claimed |
| EP-3070090-A1 | USE OF SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H- PYRAZOL-1-YL)-3- CYCLOPENTYLPROPANENITRILE | Incyte Holdings Corporation (US) | 2016-09-21 | — | — | EP | claimed |
| EP-2740731-B1 | CRYSTALLINE SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE | INCYTE HOLDINGS CORP (US) | 2016-03-23 | — | — | EP | claimed |
| EP-2740731-A1 | SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE | Incyte Corporation (US) | 2014-06-11 | — | — | EP | claimed |
| EP-2173752-B1 | SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO(2,3-D)PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE | INCYTE CORP (US) | 2014-03-19 | — | — | EP | claimed |
| EP-2173752-A2 | SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLOÝ2,3-D¨PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE | Incyte Corporation (US) | 2010-04-14 | — | — | EP | claimed |
| WO-2008157208-A2 | SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE | INCYTE CORPORATION (US) | 2008-12-24 | — | — | WO | claimed |
| US-20080312259-A1 | SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE | INCYTE CORPORATION (US) | 2008-12-18 | — | — | US | claimed |
| EP-4727526-A1 | TOPICAL SKIN FORMULATIONS OF A PHARMACEUTICALLY ACCEPTABLE SALT OF RUXOLITINIB | Incyte Corporation (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| WO-2010039939-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | INCYTE CORPORATION (US) | 2010-04-08 | — | — | WO | disclosed |
| WO-2008157208-A2 | SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE | INCYTE CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080312259-A1 | SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE | INCYTE CORPORATION (US) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312259-A1 | SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE | JAK1, JAK3, JAK2 | JAK2 3/4885JAK1 1/4885JAK3 2/4885 |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | JAK2, TP53, CDKN1A | JAK2 1/4885JAK1 8/4885JAK3 91/4885 |
| US-20220288078-A1 | Salts of the Janus Kinase Inhibitor (R)-3-(4-(7h-Pyrrolo[2,3-D]Pyrimidin-4-YL)-1h-Pyrazol-1-Yl)-3- Cyclopentylpropanenitrile | JAK1, JAK3, JAK2 | JAK2 3/4885JAK1 1/4885JAK3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.